|
|
|
| Expression and clinical significance of p-CHEK2 in invasive breast cancer |
| HU Xiaohua WANG Ning WANG Yajie▲ |
| Department of Oncology, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China |
|
|
|
Abstract Objective To detect protein expression of phosphorylated chekpoint kinase 2 (P-CHEK2Thr68) in invasive breast cancer tissues and reveal the relevant clinical significance. Methods Totally 289 cases of invasive ductal breast cancer tissues were collected from January 2007 to December 2011 in Changhai Hospital Affiliated to Second Military Medical University and Shanghai Huangpu District Central Hospital. The expression of p-CHEK2Thr68 was analyzed by immunohistochemistry, and its relationship with clinicopathological parameters was analyzed. Results The positive expression rate of p-CHEK2Thr68 in breast cancer tissues was 26.0% (75/289), the positive expression rate of the adjacent tissues was 0%, the difference was statistically significant (P ＜ 0.05). P-CHEK2Thr68 expression rate in the non-lymph node metastasis group was higher than the lymph node metastasis group, the ER negative group was higher than the ER positive group, the PR negative group was higher than the PR positive group, the HER2 negative group was higher than the HER2 positive group. P-CHEK2Thr68 expression rate in the tri-negative breast cancer group was higher than non-tri-negative breast cancer group, the difference was statistically significant (P ＜ 0.05). There was no relationships between p-CHEK2Thr68 expression and the age, menstrual status, histological grade, pathological type, tumor size, TNM stage and p53 status. Conclusion Detection of p-CHEK2Thr68 protein expression by immunohistochemistry may help to investigate the biological behavior of invasive breast cancer and to develop individualized treatment strategy．
|
|
|
|
|
|
[1] Li T，Mello-Thoms C，Brennan PC. Descriptive epidemiology of breast cancer in China：incidence，mortality，survival and prevalence [J]. Breast Cancer Res Treat，2016，159（3）：395-406.
[2] Apostolou P，Papasotiriou I. Current perspectives on CHEK2 mutations in breast cancer [J]. Breast Cancer（Dove Med Press），2017，9：331-335.
[3] Cai Z，Chehab NH，Pavletich NP. Structure and activation mechanism of the CHK2 DNA damage chekpoint kinase [J]. Mol Cell，2009，35（6）：818-829.
[4] Manic G，Obrist F，Sistigu A，et al. Trial Watch：Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy [J]. Mol Cell Oncol，2015，2（4）：e1012976.
[5] Yan S，Sorrell M，Berman Z. Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress [J]. Cell Mol Life Sci，2014，71（20）：3951-3967.
[6] Gabant G，Lorphelin A，Nozerand N，et al. Autophosphorylated residues involved in the regulation of human chk2 in vitro [J]. J Mol Biol，2008，380（3）：489-503.
[7] Zannini L，Delia D，Buscemi G. CHK2 kinase in the DNA damage response and beyond [J]. J Mol Cell Biol，2014，6（6）：442-457.
[8] Carlessi L，Buscemi G，Fontanella E，et al. A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNAdamage [J]. Biochim Biophys Acta，2010，1803（10）：1213-1223.
[9] Oka K，Tanaka T，Enoki T，et al. DNA damage signaling is actvated during cancer progression in human colorectal carcinoma [J]. Cancer Biol Ther，2010，9（3）：246-252.
[10] Fan C，Quan R，Feng X，et al. ATM activation is accompanied with earlier stages of prostate tumorigenesis [J]. Biochim Biophys Acta，2006，1763（10）：1090-1097.
[11] Chou SJ，Alawi F. Expression of DNA damage response biomarkers during oral carcinogenesis [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod，2011，111（3）：346-353.
[12] Koorstra JB，Hong SM，Shi C，et al. Widespread activatio n of the DNA damage response in human pancreatic intraepithelial neoplasia [J]. Mod Pathol，2009，22（11）：1439-1445.
[13] Li XH，Li XN，Pan X，et al. Polymorphisms in checkpoint kinase 2 may contribute to lymph node metastasis from esophageal cancer [J]. Int J Clin Exp Med，2015，8（8）：13883-13886.
[14] Gu H，Qiu W，Wan Y，et al. Variant allele of CHEK2 is associated with a decreased risk of esophageal cancer lymph node metastasis in a Chinese population [J]. Mol Biol Rep，2012，39（5）：5977-5984.
[15] Wang C，Kar S，Lai X，et al. Triple negative breast cancer in Asia：An insider's view [J]. Cancer Treat Rev，2017， 62：29-38.
[16] 欧阳能勇，龚畅，姚和瑞.靶向Chk2逆转乳腺癌启动细胞化疗耐药的实验研究[J].中华普通外科学文献：电子版，2011，5（3）：198-202.
[17] Liang X，Guo Y，Figg WD，et al. The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor [J]. Chemother Res Pract，2011，2011：715469.
[18] Jiang H，Wang B，Zhang F，et al. The Expression and Clinical Outcome of pCHK2-Thr68 and pCDC25C-Ser216 in Breast Cancer [J]. Int J Mol Sci，2016，17（11）：E1803.
[19] Brandsma I，Fleuren EDG，Williamson CT，et al. Directing the use of DDR kinase inhibitors in cancer treatment[J]. Expert Opin Investig Drugs，2017，26（12）：1341-1355.
[20] Lainchbury M，Collins I. Chekpoint kinase inhibitors：a patent review（2009-2010）[J]. Expert Opin Ther Pat，2011， 21（8）：1191-1210. |
|
|
|
